Press releases

Beactica initiates drug discovery collaboration with Medivir

Beactica, the Swedish fragment-based drug discovery company, today announced that it has entered into an agreement with Medivir AB (OMX: MVIR). Under the agreement, Beactica will use its proprietary discovery platform to identify novel hits against a disease-relevant protease of therapeutic interest to Medivir. Financial... [...]

Beactica expands its drug discovery collaboration with Boehringer Ingelheim

Beactica today announced that it has expanded its collaboration with Boehringer Ingelheim. For the additional project, Beactica will use its proprietary fragment-based platform to identify novel and selective hits against oncology-relevant kinases of therapeutic interest to Boehringer Ingelheim. Financial terms of the... [...]

Beactica extends fragment-based discovery research services agreement

Beactica, the leading Swedish fragment-based drug discovery company, today announced that it has added a project under its ongoing research services agreement with Janssen Research & Development, a division of Janssen Pharmaceutica NV. Under the research services agreement, Beactica will use its proprietary drug... [...]

Beactica contributes to detailed understanding of innovative cancer drug

Beactica, the Swedish drug discovery company with world-leading expertise in molecular interactions, today announced its contribution to a key paper in the Journal of Pharmacology and Experimental Therapeutics*. As part of a collaboration with Boehringer Ingelheim, Beactica scientists provided important insights into... [...]

Beactica nominated as “Technology Rising Star” by Deloitte

Beactica, the leading Swedish fragment-based drug discovery company spun out from Uppsala University announces that it is amongst 25 companies nominated as "Technology Rising Stars” by management consultants Deloitte. "We are delighted to be one of the 25 fastest growing new technology companies in Sweden” says... [...]

Beactica announces fragment-based drug discovery agreement

Uppsala, Sweden, April 27th, 2011 Beactica, the leading Swedish fragment-based drug discovery company, today announced that it has entered into an agreement with Janssen Research & Development, a division of Janssen Pharmaceutica NV. Under the agreement, Beactica will use its proprietary drug discovery... [...]

Beactica awarded €0.7 million from EU for pioneering influenza research

Beactica, the leading Swedish fragment-based drug discovery company, today announced that it has received a grant of up to €700 000 from the EU 7th Framework Programme to support the Company’s pioneering work in the area of influenza. In the FluCure project, Beactica will apply its proprietary fragment-based... [...]